Patents by Inventor Doris Bucher

Doris Bucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza
    Patent number: 10435462
    Abstract: The invention provides antibody reagents for screening for seed viruses, in particular, antibodies that bind to one or more discontinuous epitopes in hemagglutinin (HA) polypeptide of human influenza virus (H1N1 strain). Additionally, the invention relates to compositions, kits, supports, and biologicals comprising the antibodies or fragments thereof. Also provided are nucleic acids encoding such antibodies or fragments, including, cells and/or hybridomas which generate such molecules. Additional embodiments relate to the immunogens useful in generating the antibodies, including nucleic acids encoding such immunogens, and compositions comprising such immunogens. Further embodiments relate to methods for screening for seed viruses, including human influenza type A virus seed viruses, using the antibodies or fragments thereof.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: October 8, 2019
    Assignee: VIRO DYNAMICS CORPORATION
    Inventors: Doris Bucher, Yu He, Jianhua Le, Manojkumar Ramanunninair
  • Influenza vaccine and therapy
    Patent number: 10080792
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 25, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Influenza vaccine and therapy
    Patent number: 9999662
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 19, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark R. Alfenito, Mark Baer, Doris Bucher
  • Influenza Vaccine and Therapy
    Publication number: 20170035876
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 9, 2017
    Applicant: EnGen Bio, LLC
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • HYBRID INFLUENZA SEED VIRUSES, COMPOSITIONS THEREOF, AND USE THEREOF IN THE DIAGNOSIS OR THERAPY OF INFLUENZA
    Publication number: 20160289304
    Abstract: The invention provides antibody reagents for screening for seed viruses, in particular, antibodies that bind to one or more discontinuous epitopes in hemagglutinin (HA) polypeptide of human influenza virus (H1N1 strain). Additionally, the invention relates to compositions, kits, supports, and biologicals comprising the antibodies or fragments thereof. Also provided are nucleic acids encoding such antibodies or fragments, including, cells and/or hybridomas which generate such molecules. Additional embodiments relate to the immunogens useful in generating the antibodies, including nucleic acids encoding such immunogens, and compositions comprising such immunogens. Further embodiments relate to methods for screening for seed viruses, including human influenza type A virus seed viruses, using the antibodies or fragments thereof.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 6, 2016
    Applicant: VIRO DYNAMICS CORPORATION
    Inventors: Doris BUCHER, Yu HE, Jianhua LE, Manojkumar RAMANUNNINAIR
  • INFLUENZA VACCINE AND THERAPY
    Publication number: 20150086560
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Application
    Filed: September 21, 2014
    Publication date: March 26, 2015
    Inventors: Mark R. AIfenito, Mark Baer, Doris Bucher